Healing a weak regulator

Weaknesses in India's drug regulatory regime and the constraints and questionable decisions of the drug regulator could mar the country's reputation in global markets

Topics
Coronavirus Vaccine | Indian pharma companies | Vaccine

Prosenjit Datta 

Prosenjit Datta

By now, it is abundantly clear that the world will need to live with coronavirus for some more time despite several vaccines being available. The virus mutations will require more and better vaccines to be developed.

Last year, it had briefly looked as if different players and countries had put aside their individual interests to find a solution for the pandemic jointly. There was unprecedented cooperation between multinational drug firms, research labs, biotech start-ups and governments, to develop cures for the virus. By the end of 2020 though, vaccine nationalism, vaccine politics ...

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, March 01 2021. 22:54 IST
RECOMMENDED FOR YOU
.